Zimmer Biomet (NYSE:ZBH) today announced plans to increase its planned share repurchase for the remainder of fiscal 2026.
The company now anticipates repurchasing up to $1 billion of its common stock during the fiscal year. That marks a $250 million increase from its prior assumption.
All repurchases come under the company’s existing $1.5 billion share repurchase authorization approved by the orthopedic giant’s board of directors and announced in February of this year. The Warsaw, Indiana-based company reports no changes to the size, duration or terms of that authorization.
Zimmer Biomet reported $250 million in share repurchases thus far during the fiscal year, as of its first-quarter earnings report last month.
Learn more about Zimmer Biomet in MassDevice’s Orthopedic Device Companies Special Report. Download the free report here.
Zimmer Biomet said that, under the terms of its repurchase, it may repurchase shares in the open market and/or enter into structured repurchase agreements with third parties. Timing and amount of share repurchases depend on a variety of considerations. Those include market conditions, the company’s stock price, capital availability and alternative uses of capital.
Recent highlights for Zimmer Biomet include the appointment of a new CFO, as well as the addition of a new implant to its G7 hip line, the launch of a new curved nail system and the rollout of a new foot and ankle platform.
Zimmer Biomet set its sales guidance for 2026 for revenue growth between 2.5% and 4.5%. It recently increased its adjusted EPS guidance to $8.40–8.55 from the previous $8.30–8.45.
